American Society of Clinical Oncology Annual Meeting (ASCO)

The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.

Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.

Income- and race-related disparities concerning supportive therapies for hormone receptor–positive breast cancer require further study to ensure equitable care and access for all patients, according to Melanie Wain Kier, MD, MBA.

Takayuki Yoshino, MD, PhD, spoke about the benefit of panitumumab vs bevacizumab in combination with mFOLFOX6 in the frontline treatment of patients with RAS wild-type metastatic colorectal cancer.

Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.

Patients with TRK fusion–positive disease experienced promising survival outcomes following treatment with larotrectinib vs standard of care.

Shubham Pant, MD, spoke to the potential of ELI-002 2P as a treatment for minimal residual disease positivity in patients with KRAS-mutant solid tumors.

Benjamin Cooper, MD, discussed potential future studies exploring TAK-676 plus pembrolizumab after radiation for those with solid tumors.

Patients with RET fusion–positive solid tumors continued to experience benefit from treatment with selpercatinib, according to extended follow-up from the phase 1/2 LIBRETTO-001 basket study.

Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.

Results of the phase 3 RATIONALE-309 trial demonstrate efficacy of tislelizumab added to chemotherapy for recurrent or metastatic nasopharyngeal carcinoma.

Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma.

Results from the phase 2 CRESTONE trial showed positive overall response rates in patients with solid tumors harboring NRG1 fusions treated with seribantumab monotherapy.

A phase 1 trial evaluating SOT101 plus or minus pembrolizumab indicates the safety and potential efficacy of the agent for the treatment of advanced solid tumors.

Results from a cohort of the TAPUR study showed that the combination of cobimetinib plus vemurafenib demonstrated antitumor activity among patients with BRAF mutations who are not otherwise eligible for treatment with other FDA-approved therapies.

Benefits of larotrectinib in patients with tumors harboring NTRK fusions have been established, with new data showing health-related quality of life benefits with its use.

HPV-targeting immunotherapeutic PDS0101 in combination pembrolizumab may represent a new option for patients with HPV-positive recurrent or metastatic head and neck squamous cell carcinoma.

A sustained progression-free survival benefit was observed with nivolumab plus relatlimab-rmbw vs nivolumab alone in the phase 2/3 RELATIVITY-047 trial in treatment-naïve, unresectable or metastatic melanoma.

BRAF V600 mutation–positive pediatric low-grade glioma positively responds to combination treatment with dabrafenib plus trametinib, according to data presented at 2022 ASCO.

Patients with TRK fusion–positive central nervous system tumors were observed to have increased efficacy and safety when treated with larotrectinib at long-term follow-up.

Distant metastasis-free and recurrence-free survival were better in patients with resected stage II melanoma who were treated with adjuvant pembrolizumab vs placebo.

Ifosfamide leads to slightly better event-free and overall survival vs topotecan/cyclophosphamide in relapsed or refractory Ewing sarcoma.

Without regard for tumor histology, NRG1-positive cancers treated with zenocutuzumab experienced promising efficacy and acceptable safety.

Across 3 clinical trials, investigators continued to observe durable responses with larotrectinib, which showed the importance of NTRK gene fusion testing in patients with various cancer types.

Findings from the phase 3 ROMAN trial showed a significant reduction in severe oral mucositis with receipt of avasopasem manganese during chemoradiotherapy for patients with locally advanced, nonmetastatic head and neck cancer.

Non-White Hispanic pediatric patients with neuroblastoma appear to have worse overall survival outcomes vs other patient subgroups.

Patients who are black had a longer overall survival after investment was made for public welfare programs concerning those with cancer.

A Black patient with metastatic breast cancer explained that the results of the survey show that more work must be done by all stakeholders to increase the participation in clinical trials to accurately assess treatments in diversified populations.

CancerNetwork® sat down with Sylvie Bonvalot, MD, PhD, at the 2021 ASCO Annual Meeting to talk about treatment options for high-grade or grade II sarcoma.

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.